The osteoporosis care gap in Canada
- PMID: 15068488
- PMCID: PMC420244
- DOI: 10.1186/1471-2474-5-11
The osteoporosis care gap in Canada
Abstract
Background: The presence of a fragility fracture is a major risk factor for osteoporosis, and should be an indicator for osteoporosis diagnosis and therapy. However, the extent to which patients who fracture are assessed and treated for osteoporosis is not clear.
Methods: We performed a review of the literature to identify the practice patterns in the diagnosis and treatment of osteoporosis in adults over the age of 40 who experience a fragility fracture in Canada. Searches were performed in MEDLINE (1966 to January 2, 2003) and CINAHL (1982 to February 1, 2003) databases.
Results: There is evidence of a care gap between the occurrence of a fragility fracture and the diagnosis and treatment of osteoporosis in Canada. The proportion of individuals with a fragility fracture who received an osteoporosis diagnostic test or physician diagnosis ranged from 1.7% to 50%. Therapies such as hormone replacement therapy, bisphosphonates or calcitonin were being prescribed to 5.2% to 37.5% of patients. Calcium and vitamin D supplement intake was variable, and ranged between 2.8% to 61.6% of patients.
Conclusion: Many Canadians who experience fragility fracture are not receiving osteoporosis management for the prevention of future fractures.
Similar articles
-
Fragility fractures and the osteoporosis care gap: an international phenomenon.Semin Arthritis Rheum. 2006 Apr;35(5):293-305. doi: 10.1016/j.semarthrit.2005.11.001. Semin Arthritis Rheum. 2006. PMID: 16616152
-
Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy.Cancer. 2005 Jan 15;103(2):237-41. doi: 10.1002/cncr.20766. Cancer. 2005. PMID: 15597384
-
Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada.CMAJ. 1996 Oct 15;155(8):1113-33. CMAJ. 1996. PMID: 8873639 Free PMC article.
-
7: Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual's absolute risk of fracture.Med J Aust. 2004 Mar 15;180(6):298-303. Med J Aust. 2004. PMID: 15012571 Review.
-
[Diagnosis and therapy of osteoporosis. Strategy for effective treatment after fragility fractures].Unfallchirurg. 2003 Jul;106(7):526-41. doi: 10.1007/s00113-003-0642-5. Unfallchirurg. 2003. PMID: 12883779 Review. German.
Cited by
-
An economic evaluation: Simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures.J Bone Miner Res. 2013 Feb;28(2):383-94. doi: 10.1002/jbmr.1758. J Bone Miner Res. 2013. PMID: 22991210 Free PMC article.
-
Combination of Micronutrients for Bone (COMB) Study: bone density after micronutrient intervention.J Environ Public Health. 2012;2012:354151. doi: 10.1155/2012/354151. Epub 2012 Jan 15. J Environ Public Health. 2012. PMID: 22291722 Free PMC article.
-
The theory of planned behaviour explains intentions to use antiresorptive medication after a fragility fracture.Rheumatol Int. 2017 Jun;37(6):875-882. doi: 10.1007/s00296-017-3712-7. Epub 2017 Apr 18. Rheumatol Int. 2017. PMID: 28421359
-
Closing the osteoporosis care gap: increased osteoporosis awareness among geriatrics and rehabilitation teams.BMC Geriatr. 2009 Jul 14;9:28. doi: 10.1186/1471-2318-9-28. BMC Geriatr. 2009. PMID: 19602246 Free PMC article.
-
Osteoporosis knowledge among individuals with recent fragility fracture.Orthop Nurs. 2010 Mar-Apr;29(2):99-107. doi: 10.1097/NOR.0b013e3181d2436c. Orthop Nurs. 2010. PMID: 20335769 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous